1. Home
  2. JXG vs RNTX Comparison

JXG vs RNTX Comparison

Compare JXG & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo JX Luxventure Limited

JXG

JX Luxventure Limited

N/A

Current Price

$10.10

Market Cap

98.9M

Sector

N/A

ML Signal

N/A

RNTX

Rein Therapeutics Inc.

HOLD

Current Price

$0.98

Market Cap

80.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JXG
RNTX
Founded
N/A
2001
Country
China
United States
Employees
95
10
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
98.9M
80.7M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
JXG
RNTX
Price
$10.10
$0.98
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$10.00
AVG Volume (30 Days)
5.1K
583.4K
Earning Date
05-14-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$0.77
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.23
$0.85
52 Week High
$11.80
$2.18

Technical Indicators

Market Signals
Indicator
JXG
RNTX
Relative Strength Index (RSI) 75.18 45.52
Support Level $3.57 N/A
Resistance Level N/A $1.33
Average True Range (ATR) 0.68 0.08
MACD 0.00 0.01
Stochastic Oscillator 72.03 57.14

Price Performance

Historical Comparison
JXG
RNTX

About JXG JX Luxventure Limited

JX Luxventure Group Inc is engaged in the tourism sector and supplying related products, including technology solutions, to business partners in China, both online and offline. The company operates in three segments Tourism products, Technology, and Cross board merchandise The majority of the group revenue is generated from Tourism products. The Company's operations are located in the PRC and all of the Company's revenue is derived from sales to customers in the PRC region.

About RNTX Rein Therapeutics Inc.

Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.

Share on Social Networks: